The National Drug Abuse Treatment Clinical Trials Network

国家药物滥用治疗临床试验网络

• 批准号: 8542089
• 负责人: WALTER NMN LING
• 金额: $ 56.25万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-30 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8542089
• 关键词: Address; Agonist; Behavior Therapy; Budgets; Buprenorphine; Clinical; Clinical Research; Clinical Trials Network; Collaborations; Communities; Contracts; Country; DA10; Data; Data Collection; Data Quality; Development; Doctor of Medicine; Drug abuse; Ensure; Evaluation; Funding; Health Personnel; Health Services Accessibility; Hepatic; Human Resources; Individual; Internet; Lead; Leadership; Manuals; Measures; Methadone; Methods; Mission; Modality; Monitor; Naloxone; National Institute of Drug Abuse; Network-based; Outcome; Pacific Northwest; Participant; Patients; Performance; Persons; Pharmaceutical Preparations; Population; Process; Protocols documentation; Provider; Public Health; Publications; Randomized; Regulatory Affairs; Replacement Therapy; Research; Research Activity; Research Institute; Research Personnel; Resources; Safety; Schedule; Science; Screening procedure; Services; Site; Substance abuse problem; Suicide; Technology; Testing; Time; TimeLine; Training; Training Activity; Work; addiction; base; cocaine use; community based treatment; cost; implementation research; improved; innovation; meetings; member; named group; programs; protocol development; public health relevance; racial and ethnic; symposium

DESCRIPTION (provided by applicant): Responding to RFA-DA-10-009, this application seeks renewal of the Pacific Region Node of the National Drug Abuse Treatment Clinical Trials Network (CTN) to continue improving the quality and delivery of addiction treatments that can be implemented efficiently by community-based treatment providers (CTPs). The ongoing and future research, training, and dissemination activities of the Pacific Region Node, led by Walter Ling, M.D., will serve the CTN mission "to improve the quality of drug abuse treatment throughout the country, using science as a vehicle." The Node will continue to contribute significantly to the CTN effort by its leadership and participation in innovative concept development, rigorous conduct of research, efficient management, and effective dissemination of CTN products. In the most recent funding period, for example, Node participants developed two protocols and currently lead protocol development of CTN0048, Cocaine Use Reduction with Buprenorphine (CURB). Node personnel will continue to develop and disseminate training materials and manuals for use across the CTN, to plan and host CTN-oriented conferences, and disseminate CTN-based findings through trainings, presentations, publications, and Internet-based methods. The Node's activities will advance the science and increase broad implementation of research-proven treatments in a collaborative manner with other nodes, CTN CTPs, and other providers and researchers worldwide. This renewal proposes adding two CTPs to the existing five, increasing geographic presence and racial/ethnic inclusion as well as ensuring access to every possible setting, modality, special population, and drug abuse problem. The Pacific Region Node intends to accelerate development and testing of new medications and behavioral therapies that can be integrated to achieve better outcomes. Innovation, research pacing, and relevance will be enhanced by increasing interaction with provider groups and with researchers examining potential therapies, exploiting the Node's existing partnerships while building new collaborations and involving more broad-based settings. Renewal of the Pacific Region Node will strengthen CTN efforts through collaborative work with NIDA, CTN participants, and other stakeholders. PUBLIC HEALTH RELEVANCE: To promote use of research-proven addiction treatments, the Pacific Region Node will continue its work to incorporate more broad-based settings for CTN research, resulting in greater inclusion of and service to populations that are not comprehensively served by traditional CTPs. The Node will continue collaboration with the overall CTN to identify and address addiction challenges, public health needs, and research issues.

描述（由申请人提供）：响应RFA-DA-10-009，该申请寻求续签国家药物滥用治疗临床试验网络（CTN）的太平洋地区节点，以继续改善可以通过社区基于社区的治疗提供者（CTPS）有效地实施的成瘾治疗的质量和成瘾治疗。由M.D. Walter Ling领导的太平洋地区节点的持续和未来的研究，培训和传播活动将执行CTN任务“以使用科学作为工具来提高全国药物滥用治疗的质量”。该节点将通过其领导和参与创新概念开发，严格的研究，有效管理和有效传播CTN产品来继续为CTN的努力做出重大贡献。例如，在最近的资金期间，节点参与者开发了两个协议，目前领导CTN0048的协议开发，可卡因使用丁丙诺啡（CURB）使用可卡因。节点人员将继续开发和传播培训材料和手册，以在整个CTN上使用，以计划和主持面向CTN的会议，并通过培训，演示文稿，出版物和基于Internet的方法来传播基于CTN的发现。该节点的活动将与其他节点，CTN CTP以及全球其他提供商和研究人员一起以协作方式提高科学并增加研究预先处理的治疗方法。这种续签建议将两个CTP添加到现有的五个中，增加地理存在和种族/种族包容性，并确保进入所有可能的环境，方式，特殊人群和药物滥用问题。太平洋地区的节点旨在加快可以整合以取得更好结果的新药物和行为疗法的开发和测试。通过增加与提供商群体的互动以及研究潜在疗法的研究人员的互动，利用节点的现有合作伙伴关系，同时建立新的合作并涉及更广泛的设置，从而利用了与提供者的现有合作伙伴关系，从而增强了创新，研究起搏和相关性。续签太平洋地区节点将通过与NIDA，CTN参与者和其他利益相关者的合作合作来加强CTN的努力。 公共卫生相关性：为了促进研究证实的成瘾治疗，太平洋地区节点将继续其工作，以纳入更广泛的CTN研究环境，从而更大程度地纳入了传统CTPS并未全面服务的人群。该节点将继续与整体CTN合作，以识别和解决成瘾挑战，公共卫生需求和研究问题。